MoneyWorks4Me

Check Before You Invest : Avience Biomedicals Ltd

BSE: 0 NSE: AVIENCE ISIN: INE0V9I01017
  |   Sector:  Healthcare   |   Industry:  Medical Equipment/Supplies/Accessories

Snapshot

Q.1 Which industry/sub-sector does Avience Biomedicals Ltd belong to?
Avience Biomedicals Ltd belongs to the Healthcare sector, operating specifically within the Medical Equipment/Supplies/Accessories segment.
Q.2 Is Avience Biomedicals Ltd a good quality company?
Avience Biomedicals Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Avience Biomedicals Ltd undervalued or overvalued?
Avience Biomedicals Ltd appears Overvalued, as its key valuation ratios are higher than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios Current 0-year
Historic Median
Price to Earnings 22.21 20.29
Price to Book 8.02 3.50
Price to Sales 3.7 3.15
EV to EBITDA 13.9 11.48
Q.4 Is Avience Biomedicals Ltd a good buy now?
Avience Biomedicals Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

C: How much debt does the business have and is it at a sustainable level?

Q.1 Debt to Equity ratio of Avience Biomedicals Ltd?
Avience Biomedicals Ltd Debt-to-Equity ratio is 0.97, which is above the industry average of , indicating higher debt levels in the industry.

Q.2 Debt to cash flow from operations of Avience Biomedicals Ltd?
Avience Biomedicals Ltd Debt to cash flow from operations is 6.14, which is at a unhealthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Avience Biomedicals Ltd?

Q.1 Promoter shareholding and pledge status of Avience Biomedicals Ltd?
Promoters hold 64.59% of the Avience Biomedicals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Avience Biomedicals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Avience Biomedicals Ltd vs industry peers?
Avience Biomedicals Ltd revenue CAGR is %, compared to the industry median CAGR of 19.27%, indicating slower growth and losing its market share.
Profit Metrics
Current Level 0-year
Industry Median
Revenue Growth (%) - 19.3
Gross Profit Growth (%) 175 31.5
Operating Profit Growth (%) 175 26.1
Net Profit Growth (%) 250 36.1
Operating Efficiency
Current Level 0-year
Industry Median
Asset Turnover (x) 0.99 1.03
ROE (%) - 0.95
ROCE (%) - 8.96
Cash Conversion Cycle (days) 133.04 27

Valuation & price assessment

Q.1 Stock return of Avience Biomedicals Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
9Y 5Y 3Y 1Y
Share Price
CAGR
- - - -
Q.2 Valuation ratios of Avience Biomedicals Ltd vs historical?
The current P/E ratio of 22.21 is higher than its historical median of 20.29, indicating that the stock is trading above its historical average valuation.
Q.3 How do the current valuation ratios compare with 0-year historical median and industry numbers?
Valuation Ratios Current 0-year
Historic Median
0-year
Industry Median
Price to Earnings 22.21 20.29 -
Price to Book 8.02 3.50 -
Price to Sales 3.7 3.15 -
EV to EBITDA 13.9 11.48 -

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: